|
1
|
Ryerson AB, Eheman CR, Altekruse SF, Ward
JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM,
et al: Annual report to the nation on the status of cancer,
1975–2012, featuring the increasing incidence of liver cancer.
Cancer. 122:1312–1237. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
American Cancer Society, . Cancer Facts
& Figures 2015. American Cancer Society. 2015.
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Trimbos JB, Parmar M, Vergote I, Guthrie
D, Bolis G, Colombo N, Vermorken JB, Torri V, Mangioni C, Pecorelli
S, et al: International collaborative ovarian neoplasm trial 1 and
adjuvant chemotherapy in ovarian neoplasm trial: Two parallel
randomized phase III trials of adjuvant chemotherapy in patients
with early-stage ovarian carcinoma. J Natl Cancer Inst. 95:105–112.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Committee on the State of the science in
ovarian cancer R, Board on Health Care S, Institute of M, National
Academies of Sciences E and Medicine, . Ovarian Cancers: Evolving
Paradigms in Research and Care National Academies Press (US)
Copyright 2016 by the National Academy of Sciences. All rights
reserved., . Washington (DC): 2016
|
|
6
|
Niloff JM, Knapp RC, Schaetzl E, Reynolds
C and Bast RC Jr: CA125 antigen levels in obstetric and gynecologic
patients. Obstet Gynecol. 64:703–707. 1984.PubMed/NCBI
|
|
7
|
Mor G, Visintin I, Lai Y, Zhao H, Schwartz
P, Rutherford T, Yue L, Bray-Ward P and Ward DC: Serum protein
markers for early detection of ovarian cancer. Proc Natl Acad Sci
USA. 102:pp. 7677–7682. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nossov V, Amneus M, Su F, Lang J, Janco
JM, Reddy ST and Farias-Eisner R: The early detection of ovarian
cancer: From traditional methods to proteomics. Can we really do
better than serum CA-125? Am J Obstet Gynecol. 199:215–223.
2008.PubMed/NCBI
|
|
9
|
Luo G, Xiao Z, Long J, Liu Z, Liu L, Liu
C, Xu J, Ni Q and Yu X: CA125 is superior to CA19-9 in predicting
the resectability of pancreatic cancer. J Gastrointest Surg.
17:2092–2098. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yerushalmi R, Tyldesley S, Kennecke H,
Speers C, Woods R, Knight B and Gelmon KA: Tumor markers in
metastatic breast cancer subtypes: Frequency of elevation and
correlation with outcome. Ann Oncol. 23:338–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pollán M, Varela G, Torres A, de la Torre
M, Ludeña MD, Ortega MD, Pac J, Freixenet J, Gómez G, Sebastián F,
et al: Clinical value of p53, c-erbB-2, CEA and CA125 regarding
relapse, metastasis and death in resectable non-small cell lung
cancer. Int J Cancer. 107:781–790. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim DH, Yun HY, Ryu DH, Han HS, Han JH,
Yoon SM and Youn SJ: Preoperative CA 125 is significant indicator
of curative resection in gastric cancer patients. World J
Gastroenterol. 21:1216–1221. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lewis MR, Euscher ED, Deavers MT, Silva EG
and Malpica A: Metastatic colorectal adenocarcinoma involving the
ovary with elevated serum CA125: A potential diagnostic pitfall.
Gynecol Oncol. 105:395–398. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Basal E, Eghbali-Fatourechi GZ, Kalli KR,
Hartmann LC, Goodman KM, Goode EL, Kamen BA, Low PS and Knutson KL:
Functional folate receptor alpha is elevated in the blood of
ovarian cancer patients. PLoS One. 4:e62922009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nath S and Mukherjee P: MUC1: A
multifaceted oncoprotein with a key role in cancer progression.
Trends Mol Med. 20:332–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lau SK, Weiss LM and Chu PG: Differential
expression of MUC1, MUC2, and MUC5AC in carcinomas of various
sites: An immunohistochemical study. Am J Clin Pathol. 122:61–69.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng J, Wang L, Chen H, Li L, Ma Y, Ni J
and Li Y: The role of tumour-associated MUC1 in epithelial ovarian
cancer metastasis and progression. Cancer Metastasis Rev.
32:535–551. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins
AC and Li Y: Expression of MUC1 in primary and metastatic human
epithelial ovarian cancer and its therapeutic significance. Gynecol
Oncol. 105:695–702. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yolken RH, Peterson JA, Vonderfecht SL,
Fouts ET, Midthun K and Newburg DS: Human milk mucin inhibits
rotavirus replication and prevents experimental gastroenteritis. J
Clin Invest. 90:1984–1991. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schroten H, Hanisch FG, Plogmann R, Hacker
J, Uhlenbruck G, Nobis-Bosch R and Wahn V: Inhibition of adhesion
of S-fimbriated Escherichia coli to buccal epithelial cells by
human milk fat globule membrane components: A novel aspect of the
protective function of mucins in the nonimmunoglobulin fraction.
Infect Immun. 60:2893–2899. 1992.PubMed/NCBI
|
|
21
|
Nicholson S, Bomphray CC, Thomas H,
McIndoe A, Barton D, Gore M and George AJ: A phase I trial of
idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol
Immunother. 53:809–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Verheijen RH, Massuger LF, Benigno BB,
Epenetos AA, Lopes A, Soper JT, Markowska J, Vyzula R, Jobling T,
Stamp G, et al: Phase III trial of intraperitoneal therapy with
yttrium-90-labeled HMFG1 murine monoclonal antibody in patients
with epithelial ovarian cancer after a surgically defined complete
remission. J Clin Oncol. 24:571–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Thathiah A and Carson DD: MT1-MMP mediates
MUC1 shedding independent of TACE/ADAM17. Biochem J. 382:363–373.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Carson DD: The cytoplasmic tail of MUC1: A
very busy place. Sci Signal. 1:pe352008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Levitin F, Stern O, Weiss M, Gil-Henn C,
Ziv R, Prokocimer Z, Smorodinsky NI, Rubinstein DB and Wreschner
DH: The MUC1 SEA module is a self-cleaving domain. J Biol Chem.
280:33374–33386. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stahel RA, Gilks WR, Lehmann HP and
Schenker T: Third International Workshop on lung tumor and
differentiation antigens: Overview of the results of the central
data analysis. Int J Cancer Suppl. 8:6–26. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kohno N, Inoue Y, Hamada H, Fujioka S,
Fujino S, Yokoyama A, Hiwada K, Ueda N and Akiyama M: Difference in
sero-diagnostic values among KL-6-associated mucins classified as
cluster 9. Int J Cancer Suppl. 8:81–83. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seko A, Ohkura T, Ideo H and Yamashita K:
Novel O-linked glycans containing 6′-sulfo-Gal/GalNAc of MUC1
secreted from human breast cancer YMB-S cells: Possible
carbohydrate epitopes of KL-6(MUC1) monoclonal antibody.
Glycobiology. 22:181–195. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ishikawa N, Hattori N, Yokoyama A and
Kohno N: Utility of KL-6/MUC1 in the clinical management of
interstitial lung diseases. Respir Investig. 50:3–13. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kohno N, Kyoizumi S, Awaya Y, Fukuhara H,
Yamakido M and Akiyama M: New serum indicator of interstitial
pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest.
96:68–73. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nakao M, Oguri T, Miyazaki M, Uemura T,
Takakuwa O, Kunii E, Ohkubo H, Maeno K and Sato S: Diagnosis of
ovarian cancers using thoracoscopy: Three case reports and review
of the literature. Exp Ther Med. 4:141–145. 2012.PubMed/NCBI
|
|
32
|
Kurosaki A, Hasegawa K, Kato T, Abe K,
Hanaoka T, Miyara A, O'Shannessy DJ, Somers EB, Yasuda M, Sekino T
and Fujiwara K: Serum folate receptor alpha as a biomarker for
ovarian cancer: Implications for diagnosis, prognosis and
predicting its local tumor expression. Int J Cancer. 138:1994–2002.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Heintz AP, Odicino F, Maisonneuve P, Quinn
MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S and Beller U:
Carcinoma of the ovary. FIGO 26th Annual report on the results of
treatment in gynecological cancer. Int J Gynaecol Obstet. 95 Suppl
1:S161–S192. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Youden WJ: Index for rating diagnostic
tests. Cancer. 3:32–35. 1950. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rein BJ, Gupta S, Dada R, Safi J, Michener
C and Agarwal A: Potential markers for detection and monitoring of
ovarian cancer. J Oncol. 2011:4759832011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hanaoka T, Hasegawa K, Kato T, Sato S,
Kurosaki A, Miyara A, Nagao S, Seki H, Yasuda M and Fujiwara K:
Correlation between tumor mesothelin expression and serum
mesothelin in patients with epithelial ovarian carcinoma: A
potential noninvasive biomarker for mesothelin-targeted therapy.
Mol Diagn Ther. Feb 3–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Havrilesky LJ, Whitehead CM, Rubatt JM,
Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ and Berchuck
A: Evaluation of biomarker panels for early stage ovarian cancer
detection and monitoring for disease recurrence. Gynecol Oncol.
110:374–382. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pillai K, Pourgholami MH, Chua TC and
Morris DL: MUC1 as a potential target in anticancer therapies. Am J
Clin Oncol. 38:108–118. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Murray A, Willsher P, Price MR, Dixon AR
and Robertson JF: Evaluation of the IMMULITE BR-MA and CEA assays
and comparison with immunoradiometric assays for CA15-3 and CEA in
breast cancer. Anticancer Res. 17:1945–1949. 1997.PubMed/NCBI
|
|
40
|
Gion M, Mione R, Leon AE and Dittadi R:
Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in
primary breast cancer. Clin Chem. 45:630–637. 1999.PubMed/NCBI
|
|
41
|
Engelstaedter V, Heublein S, Schumacher
AL, Lenhard M, Engelstaedter H, Andergassen U, Guenthner-Biller M,
Kuhn C, Rack B, Kupka M, et al: Mucin-1 and its relation to grade,
stage and survival in ovarian carcinoma patients. BMC Cancer.
12:6002012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Fisken J, Roulston JE, Sturgeon C, Badley
RA, Jönrup I, Aspinall L and Leonard RC: The value of the human
milk fat globule membrane antigen HMFG2 in epithelial ovarian
cancer monitoring: Comparison with CA125. Br J Cancer.
67:1065–1070. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kohno N, Akiyama M, Kyoizumi S, Hakoda M,
Kobuke K and Yamakido M: Detection of soluble tumor-associated
antigens in sera and effusions using novel monoclonal antibodies,
KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol.
18:203–216. 1988.PubMed/NCBI
|
|
44
|
Ogawa Y, Ishikawa T, Ikeda K, Nakata B,
Sawada T, Ogisawa K, Kato Y and Hirakawa K: Evaluation of serum
KL-6, a mucin-like glycoprotein, as a tumor marker for breast
cancer. Clin Cancer Res. 6:4069–4072. 2000.PubMed/NCBI
|
|
45
|
Gad A, Tanaka E, Matsumoto A, Wahab MA,
Serwah Ael-H, Attia F, Ali K, Hassouba H, el-Deeb Ael-R, Ichijyo T,
et al: Assessment of KL-6 as a tumor marker in patients with
hepatocellular carcinoma. World J Gastroenterol. 11:6607–6612.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Budiu RA, Mantia-Smaldone G, Elishaev E,
Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP and Vlad AM:
Soluble MUC1 and serum MUC1-specific antibodies are potential
prognostic biomarkers for platinum-resistant ovarian cancer. Cancer
Immunol Immunother. 60:975–984. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hasegawa M, Sinha RK, Kumar M, Alam M, Yin
L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, et al:
Intracellular targeting of the oncogenic MUC1-C protein with a
novel GO-203 nanoparticle formulation. Clin Cancer Res.
21:2338–2347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kovjazin R, Volovitz I, Kundel Y,
Rosenbaum E, Medalia G, Horn G, Smorodinsky NI, Brenner B and
Carmon L: ImMucin: A novel therapeutic vaccine with promiscuous MHC
binding for the treatment of MUC1-expressing tumors. Vaccine.
29:4676–4686. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sangha R and Butts C: L-BLP25: A peptide
vaccine strategy in non small cell lung cancer. Clin Cancer Res.
13:s4652–s4654. 2007. View Article : Google Scholar : PubMed/NCBI
|
